Onconetix
ONCO | NASDAQ
$2.91
-$0.29 (-9.20%)
At close: Nov 16, 2026, 4:00 PM ET
$2.95
+$0.04 (+1.37%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Onconetix Company Profile
Company profile explainedCompany Profile
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its development pipeline, Onconetix is advancing a Streptococcus pneumoniae vaccine candidate, designed to prevent infectious middle ear infections in children and pneumonia in the elderly. Additionally, they are working on a universal influenza vaccine intended to provide comprehensive protection against all aggressive strains of the flu virus. Furthermore, Onconetix holds a license for an advanced norovirus S&P nanoparticle virus-like particle (VLP) vaccine platform from Cincinnati Children's. This adaptable platform is being leveraged to create vaccines for various infectious diseases, such as Marburg and monkeypox, among others. Established in 2018, the company was previously known as Blue Water Biotech, Inc., before changing its name to Onconetix, Inc. in December 2023. Its corporate headquarters are located in Cincinnati, Ohio.
Key Executives
| Name | Position |
|---|---|
| David Allan White | Chief Executive Officer |
| Karina Fedasz | Interim Chief Financial Officer |
| Ali I. Fattom | Head of Science & Discovery |
| Andrew D. Skibo | Global Head of Biologics Operations |
| Brian Price | Head of Technology Strategy |
| Jay Newmark | Chief Medical Officer |
| Theodore Scott Yoho | Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2026 | 8-K | Current Report |
| Nov 09, 2026 | 8-K | Current Report |
| Nov 06, 2026 | 425 | Filing |
| Nov 06, 2026 | 8-K | Current Report |
| Nov 05, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 27, 2026 | 425 | Filing |
| Oct 26, 2026 | 8-K | Current Report |
| Oct 23, 2026 | DEFA14A | Filing |
| Oct 23, 2026 | 8-K | Current Report |
| Oct 23, 2026 | 425 | Filing |
Onconetix
| Country | United States |
| IPO Date | Feb 18, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | David Allan White |
Contact Details
201 East Fifth Street Cincinnati,
Ohio 45202 United States
Stock Details
| Ticker Symbol | ONCO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782107 |
| CUSIP Number | 68237Q500 |
| ISIN Number | US68237Q5009 |
| SIC Code | 2834 |
Recent News
- 8 days ago / businesswire.comRealbotix Provides Update on Nasdaq Listing Timeline
- 21 days ago / globenewswire.comOnconetix Acquisition Target Realbotix Launches Echo Humanoid Robot Line with Tabletop and Full Body Models Designed for Education, Wellness, and Social Engagement
- 21 days ago / globenewswire.comOnconetix Announces Reverse Stock Split
- 25 days ago / globenewswire.comOnconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
- 25 days ago / businesswire.comRealbotix Announces Additional Draw under Bridge Loan from Onconetix
- 2 months ago / globenewswire.comSRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
- 2 months ago / globenewswire.comCORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
- 2 months ago / globenewswire.comOnconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
- 2 months ago / businesswire.comRealbotix LLC Announces Bridge Loan from Onconetix
- 2 months ago / globenewswire.comOnconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
Add to Watchlist
Select watchlists to add or remove ONCO